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Letter to the Editor 
Stability of ceﬁderocol against clinically signiﬁcant 
broad-spectrum oxacillinases 
Sir, 
Production of carbapenemases is a major concern in Enter- 
obacteriaceae, Pseudomonas spp. and Acinetobacter spp. since these 
enzymes usually confer resistance to carbapenems. Three main 
β-lactamase classes group the carbapenemases, the most com- 
mon being the KPC-type Ambler class A, class B (NDM-1, VIM-1, 
IMP-1 and SPM-1 metallo-enzymes) and class D (OXA-48-like, 
OXA-40, OXA-23) enzymes with extended geographic spread 
worldwide. The OXA-48-like β-lactamases are the most prevalent 
carbapenemases in Enterobacteriaceae in Europe. Carbapenemases 
are widespread in Acinetobacter baumannii isolates, with most 
multidrug-resistant strains producing OXA-40-like and OXA-23- 
like enzymes, with OXA-23-producers being the most frequent 
carbapenemase-producing A. baumannii . 
Ceﬁderocol is a parenteral siderophore cephalosporin also 
known as S-649266 that possesses a unique mechanism for pen- 
etrating eﬃciently into Gram-negative pathogens. It uses a ‘Trojan 
horse’ strategy by binding free iron and then actively penetrates 
into the bacterial cell across the outer membrane of Gram-negative 
bacteria owing to the bacterial iron transport system. Once across 
the outer membrane, the iron dissociates and the cephalosporin 
binds to penicillin-binding proteins (PBPs), mainly PBP3, similar 
to other cephalosporins, to disrupt cell wall synthesis contribut- 
ing to a potent antimicrobial activity against Gram-negative bac- 
teria [1] . Ceﬁderocol exhibits potent in vitro and in vivo activity 
against all Gram-negative bacteria, including carbapenem-resistant 
Enterobacteriaceae, Pseudomonas aeruginosa and A. baumannii [2] . 
This study evaluated the stability of ceﬁderocol against the most 
prevalent carbapenem-hydrolysing class D β-lactamases (CHDLs) 
in Enterobacteriaceae and A. baumannii , namely OXA-48, OXA-23 
and OXA-40, regardless of their bacterial hosts. 
The bla OXA-48 , bla OXA-23 and bla OXA-40 genes were am- 
pliﬁed by PCR and were cloned into the isopropyl β- d -1- 
thiogalactopyranoside (IPTG)-inducible vectors pET24 (Novagen, 
Merck, Darmstadt, Germany) and pGEX (GE Healthcare, Switzer- 
land) giving the pET24-OXA-48, pGEX-OXA-23 and pGEX-OXA-40 
recombinant plasmids, respectively, that were subsequently 
transformed into Escherichia coli . Induction of gene expression 
was performed by adding IPTG (1 mM) to the cultures for 5 h. 
Following centrifugation, the pellet of induced bacterial cells pro- 
ducing OXA-48 was resuspended in triethanolamine buffer pH 7.2 
(20 mM) and was disrupted by sonication using a Vibra-Cell TM 
75186 sonicator (Thermo Fisher Scientiﬁc). Following ﬁltration 
using a 0.22-μm nitrocellulose ﬁlter, the crude extract was loaded 
onto a HiTrap TM Q HP anion exchange column (GE Healthcare) 
using an ÄKTAprime chromatography system (GE Healthcare). 
Presence of the β-lactamase in the ﬂow through fractions was 
monitored using nitroceﬁn (200 μM). The positive fractions were 
dialysed against piperazine buffer pH 9.5 (20 mM) and were 
loaded again onto a HiTrap TM Q HP anion exchange column and 
were eluted using a linear gradient of K 2 SO 4 (500 mM). 
Puriﬁcation of OXA-23 and OXA-40 β-lactamases followed the 
same process except that resuspension of the pellets was done in 
10 mM sodium phosphate, 140 mM NaCl and 2.7 mM KCl (pH 
7.4) and elution was done using glutathione buffer (50 mM Tris–
HCl, 10 mM glutathione, pH 8). All fractions containing puriﬁed 
β-lactamases were dialysed against sodium phosphate buffer pH 
7.0 (0.1 M) in order to perform kinetic measurements. 
Puriﬁed β-lactamases were used for kinetic measurements per- 
formed at 30 °C in sodium phosphate buffer pH 7.0 (0.1 M). Ki- 
netic parameters showed a signiﬁcant hydrolysis rate of penicillins 
and carbapenems by the OXA-48, OXA-23 and OXA-40 puriﬁed 
enzymes, respectively, which is consistent with previous studies. 
Noteworthy, no enzymatic activity was detected for ceﬁderocol, 
mirroring the susceptibility test results ( Table 1 ). 
Minimum inhibitory concentrations (MICs) were determined 
by the broth microdilution method in iron-depleted and calcium- 
adjusted Muller–Hinton broth medium (Bio-Rad). MICs showed 
that all CHDL-producing E. coli clones exhibited a high level of 
resistance to aminopenicillins and carboxypenicillins and interme- 
diate resistance to imipenem (MICs of 1, 4 and 8 mg/L for OXA- 
48, OXA-40 and OXA-23, respectively, compared with 0.06 mg/L 
for the E. coli recipient), but remained fully susceptible to ce- 
ﬁderocol with no change in the MICs (respective values being all 
at 0.03 mg/L). 
Altogether, these ﬁndings highlight the stability of ceﬁderocol 
toward the hydrolytic capacity of CHDLs. Ceﬁderocol is a mod- 
iﬁed cephalosporin molecule with an attached catechol moiety 
on the 3-position side chain that binds to ferric iron [1] . It was 
previously shown that CHDLs do not hydrolyse broad-spectrum 
cephalosporins [2] . The current data thus conﬁrm that ceﬁderocol 
act as a potent cephalosporin, even in the presence of CHDLs. 
Previous studies showed that ceﬁderocol is active against a 
wide range of carbapenemase-producers, including those belong- 
ing to classes A and B [3, 4] . Very recently, a study described the 
stability of ceﬁderocol against AmpC-producing Gram-negative iso- 
lates [5] . Here we demonstrated that the ceﬁderocol molecule is 
also stable against CHDL-producers, conﬁrming that this molecule 
represents an interesting option for treating infections caused by 
carbapenemase-producing Gram-negative bacteria. 
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Table 1
Kinetic parameters of the OXA-48, OXA-40 and OXA-23 carbapenemases.
β-Lactam OXA-48 OXA-40 OXA-23
K m (μM) k cat (s 
–1 ) k cat / K m (mM 
–1 /s –1 ) K m (μM) k cat (s 
–1 ) k cat / K m (mM 
–1 /s –1 ) K m (μM) k cat (s 
–1 ) k cat / K m (mM 
–1 /s –1 ) 
Benzylpenicillin 200 1750 8750 20 210 10 500 60 40 670
Ampicillin 1100 370 340 150 1.5 10 nd < 0.1 nd
Ticarcillin 90 70 780 70 4 50 70 7 100
Imipenem 15 1 70 50 3.5 70 80 0.5 6
Ceﬁderocol ND < 0.1 ND ND < 0.1 ND ND < 0.1 ND
nd, not determined due to instability of the hydrolysis complex; ND, not determinable due to the absence of detectable hydrolytic activity.
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